the jackson clinical knowledgebase (Jackson Laboratory)
90
Structured Review
Jackson Laboratory
the jackson clinical knowledgebase
The Jackson Clinical Knowledgebase, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clinical+knowledgebase/jackson+clinical+knowledgebase/pm40154350-4-8-12
Average 90 stars, based on 1 article reviews
The Jackson Clinical Knowledgebase, supplied by Jackson Laboratory, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/clinical+knowledgebase/jackson+clinical+knowledgebase/pm40154350-4-8-12
Average 90 stars, based on 1 article reviews
the jackson clinical knowledgebase - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Variant Assay:Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: , The Article Title: Basket Trials: Past, Present, and Future Article Snippet: Online databases have been developed to determine the predictive role of molecular alterations; these include OncoKB, Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: TP53 mutational information is from the supplementary data of Yang et al.; TP53 status of each model was classified as non-pathogenic, pathogenic, or having conflicting evidence based on annotations from OncoKB, Article Title: A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing. Article Snippet: Clinical next generation sequencing (NGS) typically relies on limited gene panels run on bulk marrow or blood.. Current computational tools for inferring clonal relationships is generally limited by the use of a small panel of pathogenic mutations to define clones.. We developed an online software (CloneTracker) that uses ‘incidentally-sequenced’ single nucleotide polymorphisms (SNPs) in the regions of recurrent somatic mutations in addition to conventional mutation data from bulk NGS gene panels to provide detailed visualizations of clonal evolution during cancer treatment, alongside clinical data. Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: Briefly, information about functional effects of TP53 mutation variants was obtained from the OncoKB and compared to the information from ClinVar, CiViC, and the Article Title: CGE25-107: Capture Efficacy of Genomic Panels for NCCN-Recommended and Clinical Trial Associated Biomarkers. Article Snippet: CGE25-107: Capture Efficacy of Genomic Panels for NCCNRecommended and Clinical Trial Associated Biomarkers Authors: J... VIEW MORE Volume/Issue: Volume 23: Issue 3.5 Online Publication Date: 28 Mar 2025 DOI: https://doi.org/10.6004/jnccn.2025.70 05 GET PERMISSIONS Introduction: Knowledge of treatment options, including FDA-approved targeted therapies and potential clinical trial eligibility, enables oncologists to develop optimal treatment plans for patients with advanced or metastatic cancer.. National guidelines strongly endorse testing for targeted therapies and patient participation in clinical trials.. This study analyzed commercially available NGS panels of varying sizes to assess their ability to capture genomic variants linked to NCCN-recommended and clinical trialassociated targeted treatments for high incidence cancers. Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: They host the Clinical Proteomics:Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: , The Article Title: Basket Trials: Past, Present, and Future Article Snippet: Online databases have been developed to determine the predictive role of molecular alterations; these include OncoKB, Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: TP53 mutational information is from the supplementary data of Yang et al.; TP53 status of each model was classified as non-pathogenic, pathogenic, or having conflicting evidence based on annotations from OncoKB, Article Title: A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing. Article Snippet: Clinical next generation sequencing (NGS) typically relies on limited gene panels run on bulk marrow or blood.. Current computational tools for inferring clonal relationships is generally limited by the use of a small panel of pathogenic mutations to define clones.. We developed an online software (CloneTracker) that uses ‘incidentally-sequenced’ single nucleotide polymorphisms (SNPs) in the regions of recurrent somatic mutations in addition to conventional mutation data from bulk NGS gene panels to provide detailed visualizations of clonal evolution during cancer treatment, alongside clinical data. Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: Briefly, information about functional effects of TP53 mutation variants was obtained from the OncoKB and compared to the information from ClinVar, CiViC, and the Article Title: CGE25-107: Capture Efficacy of Genomic Panels for NCCN-Recommended and Clinical Trial Associated Biomarkers. Article Snippet: CGE25-107: Capture Efficacy of Genomic Panels for NCCNRecommended and Clinical Trial Associated Biomarkers Authors: J... VIEW MORE Volume/Issue: Volume 23: Issue 3.5 Online Publication Date: 28 Mar 2025 DOI: https://doi.org/10.6004/jnccn.2025.70 05 GET PERMISSIONS Introduction: Knowledge of treatment options, including FDA-approved targeted therapies and potential clinical trial eligibility, enables oncologists to develop optimal treatment plans for patients with advanced or metastatic cancer.. National guidelines strongly endorse testing for targeted therapies and patient participation in clinical trials.. This study analyzed commercially available NGS panels of varying sizes to assess their ability to capture genomic variants linked to NCCN-recommended and clinical trialassociated targeted treatments for high incidence cancers. Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: They host the Biomarker Assay:Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: , The Article Title: Basket Trials: Past, Present, and Future Article Snippet: Online databases have been developed to determine the predictive role of molecular alterations; these include OncoKB, Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: TP53 mutational information is from the supplementary data of Yang et al.; TP53 status of each model was classified as non-pathogenic, pathogenic, or having conflicting evidence based on annotations from OncoKB, Article Title: A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing. Article Snippet: Clinical next generation sequencing (NGS) typically relies on limited gene panels run on bulk marrow or blood.. Current computational tools for inferring clonal relationships is generally limited by the use of a small panel of pathogenic mutations to define clones.. We developed an online software (CloneTracker) that uses ‘incidentally-sequenced’ single nucleotide polymorphisms (SNPs) in the regions of recurrent somatic mutations in addition to conventional mutation data from bulk NGS gene panels to provide detailed visualizations of clonal evolution during cancer treatment, alongside clinical data. Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: Briefly, information about functional effects of TP53 mutation variants was obtained from the OncoKB and compared to the information from ClinVar, CiViC, and the Article Title: CGE25-107: Capture Efficacy of Genomic Panels for NCCN-Recommended and Clinical Trial Associated Biomarkers. Article Snippet: CGE25-107: Capture Efficacy of Genomic Panels for NCCNRecommended and Clinical Trial Associated Biomarkers Authors: J... VIEW MORE Volume/Issue: Volume 23: Issue 3.5 Online Publication Date: 28 Mar 2025 DOI: https://doi.org/10.6004/jnccn.2025.70 05 GET PERMISSIONS Introduction: Knowledge of treatment options, including FDA-approved targeted therapies and potential clinical trial eligibility, enables oncologists to develop optimal treatment plans for patients with advanced or metastatic cancer.. National guidelines strongly endorse testing for targeted therapies and patient participation in clinical trials.. This study analyzed commercially available NGS panels of varying sizes to assess their ability to capture genomic variants linked to NCCN-recommended and clinical trialassociated targeted treatments for high incidence cancers. Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: They host the Biomarker Discovery:Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: , The Article Title: Basket Trials: Past, Present, and Future Article Snippet: Online databases have been developed to determine the predictive role of molecular alterations; these include OncoKB, Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: TP53 mutational information is from the supplementary data of Yang et al.; TP53 status of each model was classified as non-pathogenic, pathogenic, or having conflicting evidence based on annotations from OncoKB, Article Title: A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing. Article Snippet: Clinical next generation sequencing (NGS) typically relies on limited gene panels run on bulk marrow or blood.. Current computational tools for inferring clonal relationships is generally limited by the use of a small panel of pathogenic mutations to define clones.. We developed an online software (CloneTracker) that uses ‘incidentally-sequenced’ single nucleotide polymorphisms (SNPs) in the regions of recurrent somatic mutations in addition to conventional mutation data from bulk NGS gene panels to provide detailed visualizations of clonal evolution during cancer treatment, alongside clinical data. Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: Briefly, information about functional effects of TP53 mutation variants was obtained from the OncoKB and compared to the information from ClinVar, CiViC, and the Article Title: CGE25-107: Capture Efficacy of Genomic Panels for NCCN-Recommended and Clinical Trial Associated Biomarkers. Article Snippet: CGE25-107: Capture Efficacy of Genomic Panels for NCCNRecommended and Clinical Trial Associated Biomarkers Authors: J... VIEW MORE Volume/Issue: Volume 23: Issue 3.5 Online Publication Date: 28 Mar 2025 DOI: https://doi.org/10.6004/jnccn.2025.70 05 GET PERMISSIONS Introduction: Knowledge of treatment options, including FDA-approved targeted therapies and potential clinical trial eligibility, enables oncologists to develop optimal treatment plans for patients with advanced or metastatic cancer.. National guidelines strongly endorse testing for targeted therapies and patient participation in clinical trials.. This study analyzed commercially available NGS panels of varying sizes to assess their ability to capture genomic variants linked to NCCN-recommended and clinical trialassociated targeted treatments for high incidence cancers. Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: They host the Functional Assay:Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: , The Article Title: Basket Trials: Past, Present, and Future Article Snippet: Online databases have been developed to determine the predictive role of molecular alterations; these include OncoKB, Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: TP53 mutational information is from the supplementary data of Yang et al.; TP53 status of each model was classified as non-pathogenic, pathogenic, or having conflicting evidence based on annotations from OncoKB, Article Title: A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing. Article Snippet: Clinical next generation sequencing (NGS) typically relies on limited gene panels run on bulk marrow or blood.. Current computational tools for inferring clonal relationships is generally limited by the use of a small panel of pathogenic mutations to define clones.. We developed an online software (CloneTracker) that uses ‘incidentally-sequenced’ single nucleotide polymorphisms (SNPs) in the regions of recurrent somatic mutations in addition to conventional mutation data from bulk NGS gene panels to provide detailed visualizations of clonal evolution during cancer treatment, alongside clinical data. Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: Briefly, information about functional effects of TP53 mutation variants was obtained from the OncoKB and compared to the information from ClinVar, CiViC, and the Article Title: CGE25-107: Capture Efficacy of Genomic Panels for NCCN-Recommended and Clinical Trial Associated Biomarkers. Article Snippet: CGE25-107: Capture Efficacy of Genomic Panels for NCCNRecommended and Clinical Trial Associated Biomarkers Authors: J... VIEW MORE Volume/Issue: Volume 23: Issue 3.5 Online Publication Date: 28 Mar 2025 DOI: https://doi.org/10.6004/jnccn.2025.70 05 GET PERMISSIONS Introduction: Knowledge of treatment options, including FDA-approved targeted therapies and potential clinical trial eligibility, enables oncologists to develop optimal treatment plans for patients with advanced or metastatic cancer.. National guidelines strongly endorse testing for targeted therapies and patient participation in clinical trials.. This study analyzed commercially available NGS panels of varying sizes to assess their ability to capture genomic variants linked to NCCN-recommended and clinical trialassociated targeted treatments for high incidence cancers. Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: They host the Mutagenesis:Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: , The Article Title: Basket Trials: Past, Present, and Future Article Snippet: Online databases have been developed to determine the predictive role of molecular alterations; these include OncoKB, Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: TP53 mutational information is from the supplementary data of Yang et al.; TP53 status of each model was classified as non-pathogenic, pathogenic, or having conflicting evidence based on annotations from OncoKB, Article Title: A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing. Article Snippet: Clinical next generation sequencing (NGS) typically relies on limited gene panels run on bulk marrow or blood.. Current computational tools for inferring clonal relationships is generally limited by the use of a small panel of pathogenic mutations to define clones.. We developed an online software (CloneTracker) that uses ‘incidentally-sequenced’ single nucleotide polymorphisms (SNPs) in the regions of recurrent somatic mutations in addition to conventional mutation data from bulk NGS gene panels to provide detailed visualizations of clonal evolution during cancer treatment, alongside clinical data. Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: Briefly, information about functional effects of TP53 mutation variants was obtained from the OncoKB and compared to the information from ClinVar, CiViC, and the Article Title: CGE25-107: Capture Efficacy of Genomic Panels for NCCN-Recommended and Clinical Trial Associated Biomarkers. Article Snippet: CGE25-107: Capture Efficacy of Genomic Panels for NCCNRecommended and Clinical Trial Associated Biomarkers Authors: J... VIEW MORE Volume/Issue: Volume 23: Issue 3.5 Online Publication Date: 28 Mar 2025 DOI: https://doi.org/10.6004/jnccn.2025.70 05 GET PERMISSIONS Introduction: Knowledge of treatment options, including FDA-approved targeted therapies and potential clinical trial eligibility, enables oncologists to develop optimal treatment plans for patients with advanced or metastatic cancer.. National guidelines strongly endorse testing for targeted therapies and patient participation in clinical trials.. This study analyzed commercially available NGS panels of varying sizes to assess their ability to capture genomic variants linked to NCCN-recommended and clinical trialassociated targeted treatments for high incidence cancers. Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: They host the Derivative Assay:Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: , The Article Title: Basket Trials: Past, Present, and Future Article Snippet: Online databases have been developed to determine the predictive role of molecular alterations; these include OncoKB, Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: TP53 mutational information is from the supplementary data of Yang et al.; TP53 status of each model was classified as non-pathogenic, pathogenic, or having conflicting evidence based on annotations from OncoKB, Article Title: A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing. Article Snippet: Clinical next generation sequencing (NGS) typically relies on limited gene panels run on bulk marrow or blood.. Current computational tools for inferring clonal relationships is generally limited by the use of a small panel of pathogenic mutations to define clones.. We developed an online software (CloneTracker) that uses ‘incidentally-sequenced’ single nucleotide polymorphisms (SNPs) in the regions of recurrent somatic mutations in addition to conventional mutation data from bulk NGS gene panels to provide detailed visualizations of clonal evolution during cancer treatment, alongside clinical data. Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: Briefly, information about functional effects of TP53 mutation variants was obtained from the OncoKB and compared to the information from ClinVar, CiViC, and the Article Title: CGE25-107: Capture Efficacy of Genomic Panels for NCCN-Recommended and Clinical Trial Associated Biomarkers. Article Snippet: CGE25-107: Capture Efficacy of Genomic Panels for NCCNRecommended and Clinical Trial Associated Biomarkers Authors: J... VIEW MORE Volume/Issue: Volume 23: Issue 3.5 Online Publication Date: 28 Mar 2025 DOI: https://doi.org/10.6004/jnccn.2025.70 05 GET PERMISSIONS Introduction: Knowledge of treatment options, including FDA-approved targeted therapies and potential clinical trial eligibility, enables oncologists to develop optimal treatment plans for patients with advanced or metastatic cancer.. National guidelines strongly endorse testing for targeted therapies and patient participation in clinical trials.. This study analyzed commercially available NGS panels of varying sizes to assess their ability to capture genomic variants linked to NCCN-recommended and clinical trialassociated targeted treatments for high incidence cancers. Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: They host the Inhibition:Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: , The Article Title: Basket Trials: Past, Present, and Future Article Snippet: Online databases have been developed to determine the predictive role of molecular alterations; these include OncoKB, Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: TP53 mutational information is from the supplementary data of Yang et al.; TP53 status of each model was classified as non-pathogenic, pathogenic, or having conflicting evidence based on annotations from OncoKB, Article Title: A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing. Article Snippet: Clinical next generation sequencing (NGS) typically relies on limited gene panels run on bulk marrow or blood.. Current computational tools for inferring clonal relationships is generally limited by the use of a small panel of pathogenic mutations to define clones.. We developed an online software (CloneTracker) that uses ‘incidentally-sequenced’ single nucleotide polymorphisms (SNPs) in the regions of recurrent somatic mutations in addition to conventional mutation data from bulk NGS gene panels to provide detailed visualizations of clonal evolution during cancer treatment, alongside clinical data. Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: Briefly, information about functional effects of TP53 mutation variants was obtained from the OncoKB and compared to the information from ClinVar, CiViC, and the Article Title: CGE25-107: Capture Efficacy of Genomic Panels for NCCN-Recommended and Clinical Trial Associated Biomarkers. Article Snippet: CGE25-107: Capture Efficacy of Genomic Panels for NCCNRecommended and Clinical Trial Associated Biomarkers Authors: J... VIEW MORE Volume/Issue: Volume 23: Issue 3.5 Online Publication Date: 28 Mar 2025 DOI: https://doi.org/10.6004/jnccn.2025.70 05 GET PERMISSIONS Introduction: Knowledge of treatment options, including FDA-approved targeted therapies and potential clinical trial eligibility, enables oncologists to develop optimal treatment plans for patients with advanced or metastatic cancer.. National guidelines strongly endorse testing for targeted therapies and patient participation in clinical trials.. This study analyzed commercially available NGS panels of varying sizes to assess their ability to capture genomic variants linked to NCCN-recommended and clinical trialassociated targeted treatments for high incidence cancers. Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: They host the Modification:Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: , The Article Title: Basket Trials: Past, Present, and Future Article Snippet: Online databases have been developed to determine the predictive role of molecular alterations; these include OncoKB, Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: TP53 mutational information is from the supplementary data of Yang et al.; TP53 status of each model was classified as non-pathogenic, pathogenic, or having conflicting evidence based on annotations from OncoKB, Article Title: A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing. Article Snippet: Clinical next generation sequencing (NGS) typically relies on limited gene panels run on bulk marrow or blood.. Current computational tools for inferring clonal relationships is generally limited by the use of a small panel of pathogenic mutations to define clones.. We developed an online software (CloneTracker) that uses ‘incidentally-sequenced’ single nucleotide polymorphisms (SNPs) in the regions of recurrent somatic mutations in addition to conventional mutation data from bulk NGS gene panels to provide detailed visualizations of clonal evolution during cancer treatment, alongside clinical data. Article Title: Insights into gemcitabine resistance in pancreatic cancer: association with metabolic reprogramming and TP53 pathogenicity in patient derived xenografts Article Snippet: Briefly, information about functional effects of TP53 mutation variants was obtained from the OncoKB and compared to the information from ClinVar, CiViC, and the Article Title: CGE25-107: Capture Efficacy of Genomic Panels for NCCN-Recommended and Clinical Trial Associated Biomarkers. Article Snippet: CGE25-107: Capture Efficacy of Genomic Panels for NCCNRecommended and Clinical Trial Associated Biomarkers Authors: J... VIEW MORE Volume/Issue: Volume 23: Issue 3.5 Online Publication Date: 28 Mar 2025 DOI: https://doi.org/10.6004/jnccn.2025.70 05 GET PERMISSIONS Introduction: Knowledge of treatment options, including FDA-approved targeted therapies and potential clinical trial eligibility, enables oncologists to develop optimal treatment plans for patients with advanced or metastatic cancer.. National guidelines strongly endorse testing for targeted therapies and patient participation in clinical trials.. This study analyzed commercially available NGS panels of varying sizes to assess their ability to capture genomic variants linked to NCCN-recommended and clinical trialassociated targeted treatments for high incidence cancers. Article Title: Precision oncology platforms: practical strategies for genomic database utilization in cancer treatment Article Snippet: They host the |